Skip to content

A real-world study of molecular residue detection (MRD) status in advanced breast cancer that achieves PET remission

A real-world study of molecular residue detection (MRD) status in advanced breast cancer that achieves PET remission

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071524
Enrollment
Unknown
Registered
2023-05-17
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Observation group:None

Sponsors

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1). Age= 18 years old. (2). Histological confirmation of breast cancer and surgery can not remove all metastatic lesions. (3). After comprehensive treatment, routine imaging examination achieves significant relief, which meets one of the following two items: The image is completely mitigated; CT or MRI shows that the tumor lesion is persistently stable, has received radiotherapy, or has been stable for at least 6 months. (4). Subject has paraffin embedded tumor tissue within two years. (5). Subject agrees to participate in the study and has signed an informed consent form. (6). Be able to follow the study protocol and follow-up process.

Exclusion criteria

Exclusion criteria: (1). Patients diagnosed with any malignant tumor within the past 5 years; (2). Suffering from other serious systemic diseases at the same time, which the investigator believes may interfere with the treatment, evaluation and compliance of this trial, including severe respiratory, circulatory, nervous, mental, digestive, endocrine, immune, urinary and other systemic diseases; (3). The investigator judges that the patient is not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Molecular residue detection;

Secondary

MeasureTime frame
immune index;

Countries

China

Contacts

Public ContactLi Xie

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

sherry01130@163.com+86 136 0516 9652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026